ArticleHealthcare (Basel, Switzerland)2026
Respiratory Muscle Performance and Pulmonary Function in Sarcopenic and Non-Sarcopenic Patients with Multiple Sclerosis: A Cross-Sectional Study.
Article in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory muscle dysfunction is a recognized complication of multiple sclerosis (MS) and may contribute to functional decline. Sarcopenia related to neurological impairment may further impair respiratory muscle performance in MS. This study aimed to investigate the association between sarcopenia and respiratory function, respiratory muscle strength, and respiratory muscle endurance in patients with MS.
methodsThis study was designed as a cross-sectional observational study. In this study, 52 MS patients (26 sarcopenic, 26 non-sarcopenic) were evaluated. Sarcopenia was assessed using the SARC-F questionnaire, handgrip strength, bioelectrical impedance analysis, calf circumference, and walking speed (6-m walk test). Pulmonary function was evaluated using spirometry. Respiratory muscle strength was assessed using maximal inspiratory and expiratory pressures (MIP, MEP), and respiratory muscle endurance was evaluated using a constant-load test.
resultsRespiratory muscle endurance (
conclusionsSarcopenia is associated with reduced respiratory muscle endurance and respiratory capacity in patients with MS. These findings suggest that respiratory muscle endurance assessment may help identify sarcopenic MS patients who warrant further respiratory evaluation. Incorporating respiratory muscle endurance assessment into routine evaluation and rehabilitation strategies may be beneficial in sarcopenic MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.